ACE2 and COVID-19: Current clinical trials of recombinant human ACE2 focus on neutralizing COVID-19 (clinicaltrials.gov) and activating the systemic protective axis of the renin angiotensin aldosterone pathway.28 However, it is unknown whether the suggested detrimental release of soluble ACE2 from cells can be attenuated through systemic ACE2 delivery to improve cardiovascular outcomes.